A narrative review in Haemophilia proposes that GLP-1 signaling pathways may be relevant to hemophilic arthropathy, drawing on osteoarthritis and inflammatory arthritis literature. The authors state that GLP-1 receptor agonists have not yet been studied directly in hemophilia.
Nox Peptides has launched GHK-Cu and a combination product containing BPC-157 and TB-500 for Canadian research buyers, the company said in an October 6 announcement. No trial, outcome figure or published study accompanies the launch, and the release makes no health claims.
A September 2026 preprint identified 1,039 documented BPC-157 users and a roughly 33-fold rise in new users since 2020, while the named human studies behind the peptide involve 16 people and two people. Here is what the research actually reports, and the large amount it does not.
Sports medicine physician Jordan D. Metzl argues that semaglutide's randomized trial data should not be confused with the evidence behind BPC-157, TB-500, CJC-1295 and ipamorelin. He says he wants more peptide research, not fewer questions about it.
A September 2026 preprint analyzing 15 million medical records found a roughly 33-fold rise in documented BPC-157 users between 2020 and 2026, with pain relief the dominant reason given. Human evidence remains limited to preclinical work and very small studies, and an FDA advisory panel's 8-6 compounding vote did not change that.
A research overview of BPC-157 in the UK says current information identifies no MHRA marketing authorization for the peptide, and that most of the evidence remains preclinical. It also argues that "research use" labeling offers no assurance about human safety.
An FDA advisory committee voted in July to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon for the 503A Bulks List, rejecting only emideltide. A Houston clinic is warning patients that the vote carries no immediate legal effect and that the rulemaking process has not started.
TB-500 is a seven-amino-acid fragment of thymosin beta-4, and FDA states the two are different substances. A review of the evidence finds a cell migration hypothesis, one unhelpful 2024 lab result, and no published human studies at all.
A sponsored comparison on Medical News Bulletin lays out how BPC-157 and TB-500 differ, and the widest gap is in human data: five small published studies versus none. FDA's briefing also states plainly that TB-500 and thymosin beta-4 are different substances, which undercuts much of the literature quoted for it.
Recent collagen peptide research spans frozen dough stabilization and cell-culture hydrogel scaffolds, alongside a new consumer gummy launch. None of it reports a human clinical outcome, which is worth knowing before reading the marketing.
A preprint curating U.S. clinical notes found BPC-157 use rose 33-fold between 2020 and 2026, with pain and gastrointestinal conditions the most documented reasons. The authors say the records cannot establish efficacy, and the peptide's compounding status remains unresolved.
An Allure beauty editor tested a $350 compounded GHK-Cu cream for eight weeks, then asked a dermatologist, a pharmacist and a cosmetic chemist whether the prescription route was worth it. All three were skeptical, and the published human data on copper peptides remains small and largely brand-funded.
Beyond Raw's Chemistry Labs series is adding a Collagen Peptides powder built on 5g of Gelita's Tendoforte, priced at $24.99 for 30 servings at GNC. The supplier says the ingredient can enhance joint stability and tendon thickness alongside resistance training, but no study is named anywhere in the announcement.
Karnataka's drug regulator served notice on a Bengaluru "peptide party" featuring peptide tastings, and the event was canceled. Doctors quoted in the report warn that approved peptide medicines and experimental compounds sold online are not the same category.
The FDA had logged 990 adverse-event reports tied to compounded semaglutide and more than 730 involving compounded tirzepatide as of the end of May, WBAY reports. Experts quoted say online availability of unapproved peptide products is being mistaken for legality.
GHK-Cu has decades of mechanistic and cell-culture research behind it, and dermatologists say its wound-healing history is the most clinically established part. Controlled human trials on the aging-skin uses it is now marketed for remain thin.
A Hartford Hospital explainer argues that "peptide therapy" now covers everything from insulin to unstudied injections sold online, with very different evidence behind each. Physician Joe Li, DO, says the wellness-clinic peptides like BPC-157, ipamorelin and CJC-1295 have mostly been researched in labs and animals rather than people.
Bengaluru's first invite-only "Peptide Party" was canceled after drawing more than 200 registrations for around 50 places, but The Indian Express reports the demand behind it is the real story. Researchers and the US FDA point to thin human evidence, contaminated samples and mislabeled vials in the online peptide market.
Researchers and clinicians quoted in a Women's Health feature say synthetic injectable peptides sold for fitness, recovery and sleep are not supported by solid research, with GLP-1 drugs the exception. One endocrinologist calls the legal status a gray zone, and an oncologist calls the trend totally insane.
A mouse study in the European Journal of Pharmacology reports that the GLP-1 receptor agonist dulaglutide reduced serum ALT and AST and altered ferroptosis-related markers in a diabetic model of fatty liver disease. The work was done entirely in db/db mice, and the published abstract gives no doses, group sizes or effect sizes.
A prospective cohort study in Clinical Nutrition reports that elevated plasma GLP-1 was associated with enteral feeding intolerance in patients with traumatic brain injury. The authors are careful to call the result hypothesis-generating rather than conclusive.
